FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890799019> ?p ?o ?g. }

• W2890799019 endingPage "229" @default.
• W2890799019 startingPage "222" @default.
• W2890799019 abstract "Purpose Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC). Materials and Methods Patients with ES-SCLC, stratified by sex and serum lactate dehydrogenase levels, were randomly assigned to receive four 3-week cycles of CE (75 mg/m 2 intravenously on day 1 and 100 mg/m 2 on days 1 through 3) along with veliparib (100 mg orally twice per day on days 1 through 7) or placebo (CE+P). The primary end point was progression-free survival (PFS). Using an overall one-sided 0.10-level log-rank test, the study had 88% power to demonstrate a 37.5% reduction in the PFS hazard rate. Results A total of 128 eligible patients received treatment on protocol. The median age was 66 years, 52% of patients were men, and Eastern Cooperative Oncology Group performance status was 0 for 29% of patients and 1 for 71%. The respective median PFS for the CE+V arm versus the CE+P arm was 6.1 versus 5.5 months (unstratified hazard ratio [HR], 0.75 [one-sided P = .06]; stratified HR, 0.63 [one-sided P = .01]), favoring CE+V. The median overall survival was 10.3 versus 8.9 months (stratified HR, 0.83; 80% CI, 0.64 to 1.07; one-sided P = .17) for the CE+V and CE+P arms, respectively. The overall response rate was 71.9% versus 65.6% (two-sided P = .57) for CE+V and CE+P, respectively. There was a significant treatment-by-strata interaction in PFS: Male patients with high lactate dehydrogenase levels derived significant benefit (PFS HR, 0.34; 80% CI, 0.22 to 0.51) but there was no evidence of benefit among patients in other strata (PFS HR, 0.81; 80% CI, 0.60 to 1.09). The following grade ≥ 3 hematology toxicities were more frequent in the CE+V arm than the CE+P arm: CD4 lymphopenia (8% v 0%; P = .06) and neutropenia (49% v 32%; P = .08), but treatment delivery was comparable. Conclusion The addition of veliparib to frontline chemotherapy showed signal of efficacy in patients with ES-SCLC and the study met its prespecified end point." @default.
• W2890799019 created "2018-09-27" @default.
• W2890799019 creator A5011486016 @default.
• W2890799019 creator A5013977667 @default.
• W2890799019 creator A5015060656 @default.
• W2890799019 creator A5018666301 @default.
• W2890799019 creator A5023971012 @default.
• W2890799019 creator A5044834942 @default.
• W2890799019 creator A5047818279 @default.
• W2890799019 creator A5056098854 @default.
• W2890799019 creator A5070120524 @default.
• W2890799019 creator A5079064611 @default.
• W2890799019 creator A5088178599 @default.
• W2890799019 date "2019-01-20" @default.
• W2890799019 modified "2023-10-16" @default.
• W2890799019 title "Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study" @default.
• W2890799019 cites W1541747338 @default.
• W2890799019 cites W1918894023 @default.
• W2890799019 cites W1975473230 @default.
• W2890799019 cites W1980721628 @default.
• W2890799019 cites W2049732302 @default.
• W2890799019 cites W2086038769 @default.
• W2890799019 cites W2094666871 @default.
• W2890799019 cites W2098161852 @default.
• W2890799019 cites W2098737737 @default.
• W2890799019 cites W2101663915 @default.
• W2890799019 cites W2112241575 @default.
• W2890799019 cites W2138878490 @default.
• W2890799019 cites W2145708352 @default.
• W2890799019 cites W2150878803 @default.
• W2890799019 cites W2166418266 @default.
• W2890799019 cites W2170260373 @default.
• W2890799019 cites W2500891884 @default.
• W2890799019 cites W2528953057 @default.
• W2890799019 cites W2571386539 @default.
• W2890799019 cites W2588635345 @default.
• W2890799019 cites W2588648082 @default.
• W2890799019 cites W2590243799 @default.
• W2890799019 cites W2592941899 @default.
• W2890799019 cites W2599047065 @default.
• W2890799019 cites W2740934820 @default.
• W2890799019 cites W2744945030 @default.
• W2890799019 cites W2767946716 @default.
• W2890799019 cites W2808238124 @default.
• W2890799019 doi "https://doi.org/10.1200/jco.18.00264" @default.
• W2890799019 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6338394" @default.
• W2890799019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30523756" @default.
• W2890799019 hasPublicationYear "2019" @default.
• W2890799019 type Work @default.
• W2890799019 sameAs 2890799019 @default.
• W2890799019 citedByCount "111" @default.
• W2890799019 countsByYear W28907990192018 @default.
• W2890799019 countsByYear W28907990192019 @default.
• W2890799019 countsByYear W28907990192020 @default.
• W2890799019 countsByYear W28907990192021 @default.
• W2890799019 countsByYear W28907990192022 @default.
• W2890799019 countsByYear W28907990192023 @default.
• W2890799019 crossrefType "journal-article" @default.
• W2890799019 hasAuthorship W2890799019A5011486016 @default.
• W2890799019 hasAuthorship W2890799019A5013977667 @default.
• W2890799019 hasAuthorship W2890799019A5015060656 @default.
• W2890799019 hasAuthorship W2890799019A5018666301 @default.
• W2890799019 hasAuthorship W2890799019A5023971012 @default.
• W2890799019 hasAuthorship W2890799019A5044834942 @default.
• W2890799019 hasAuthorship W2890799019A5047818279 @default.
• W2890799019 hasAuthorship W2890799019A5056098854 @default.
• W2890799019 hasAuthorship W2890799019A5070120524 @default.
• W2890799019 hasAuthorship W2890799019A5079064611 @default.
• W2890799019 hasAuthorship W2890799019A5088178599 @default.
• W2890799019 hasBestOaLocation W28907990192 @default.
• W2890799019 hasConcept C104317684 @default.
• W2890799019 hasConcept C126322002 @default.
• W2890799019 hasConcept C126894567 @default.
• W2890799019 hasConcept C141071460 @default.
• W2890799019 hasConcept C142724271 @default.
• W2890799019 hasConcept C143998085 @default.
• W2890799019 hasConcept C168563851 @default.
• W2890799019 hasConcept C182979987 @default.
• W2890799019 hasConcept C185592680 @default.
• W2890799019 hasConcept C203092338 @default.
• W2890799019 hasConcept C204787440 @default.
• W2890799019 hasConcept C207103383 @default.
• W2890799019 hasConcept C27081682 @default.
• W2890799019 hasConcept C2776256026 @default.
• W2890799019 hasConcept C2776694085 @default.
• W2890799019 hasConcept C2778119113 @default.
• W2890799019 hasConcept C2778239845 @default.
• W2890799019 hasConcept C2781312401 @default.
• W2890799019 hasConcept C44249647 @default.
• W2890799019 hasConcept C55493867 @default.
• W2890799019 hasConcept C71924100 @default.
• W2890799019 hasConcept C82381507 @default.
• W2890799019 hasConcept C90924648 @default.
• W2890799019 hasConceptScore W2890799019C104317684 @default.
• W2890799019 hasConceptScore W2890799019C126322002 @default.
• W2890799019 hasConceptScore W2890799019C126894567 @default.
• W2890799019 hasConceptScore W2890799019C141071460 @default.
• W2890799019 hasConceptScore W2890799019C142724271 @default.

• next